BioNTech shots trigger more antibodies than Sinovac: study
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[HONG KONG] The BioNTech Covid-19 vaccine triggered "substantially higher" levels of antibodies compared to the Chinese-made Sinovac jab, the South China Morning Post reported Saturday, citing a study by the University of Hong Kong.
The results suggested some recipients of the Sinovac vaccine may need a third shot, the newspaper said, citing lead researcher Benjamin Cowling. The epidemiologist led the government-commissioned study that tracked antibody responses of 1,000 vaccinated people.
Cowling warned antibody tests might fail to pick up small amounts of antibodies generated by the Sinovac jabs. He was commenting on a recommendation by the government's scientific advisers to cut quarantine time for vaccinated travelers who test positive for antibodies but negative for the virus, the newspaper said.
BLOOMBERG
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance